Key Takeaways
- Ipsen’s study on fidrisertib for fibrodysplasia ossificans progressiva (FOP) failed to show effectiveness, leading to early termination.
- The trial, involving 113 participants, aimed to evaluate the drug’s impact on new bone formation but did not meet primary goals.
- Despite the disappointing results, Ipsen believes the data will enhance understanding of FOP and future treatment strategies.
Fidrisertib Trial Results Prompt Early Termination
Ipsen announced the early termination of its pivotal Phase 2 trial, known as FALKON, after its oral small molecule, fidrisertib, failed to significantly reduce the progression of fibrodysplasia ossificans progressiva (FOP). The announcement was made on December 19, 2023, but specific data regarding the trial outcomes were not disclosed.
FALKON initiated in 2021 and included 113 adults and children diagnosed with FOP, a rare genetic disorder characterized by the abnormal transformation of soft tissues into bone. The trial aimed to assess the efficacy of fidrisertib in preventing new heterotopic ossifications, a condition where bone forms in connective tissues and is irreversible once established. The study’s main goal was to analyze changes in ossification volume over time compared to a placebo, with primary results anticipated in 2029.
The trial was structured in three phases. In the initial phase, participants were administered either high or low doses of fidrisertib depending on their body weight or given a placebo. The second phase allowed individuals who initially received a placebo to switch to either high or low doses of the drug. The final phase was an extension for those who benefited from the treatment.
Despite the lack of efficacy data, Ipsen reported that fidrisertib was generally well tolerated, with no safety concerns raised during the trial. Dr. Christelle Huguet, Ipsen’s R&D head, expressed disappointment regarding the results, highlighting the impact this outcome would have on the FOP community. However, she emphasized that the findings could contribute valuable insights for patients and healthcare providers managing this challenging disease.
FOP significantly limits the life expectancy of affected individuals, which averages around 56 years. The disease often leads to complications, such as restricted breathing due to bone formations around the rib cage. Currently, about 900 individuals globally are diagnosed with this condition and viable treatment options remain scarce. In 2023, Ipsen secured FDA approval for Sohonos, a retinoid therapy for FOP; however, its commercial performance has been lackluster, reflecting a 20% sales decline to 8.3 million euros in the first half of 2025.
Ipsen had pinned its hopes on fidrisertib to improve upon the challenges faced by Sohonos regarding safety concerns and market reception. Fidrisertib targets pathogenic variants of the ALK2 kinase, a leading cause of FOP in patients with specific genetic mutations.
In contrast to Ipsen’s setback, Regeneron Pharmaceuticals successfully reported results from a Phase 3 trial in the same indication. Their drug, garetosmab, demonstrated over a 90% reduction in abnormal bone lesions, leading to plans for FDA approval submission by the end of 2025. However, Regeneron’s path has not been without difficulties, including a trial pause in 2020 due to patient fatalities during an extension phase. Researchers later concluded that these incidents were unlikely linked to the drug.
As the landscape of FOP treatments evolves, both Ipsen and Regeneron highlight the ongoing need for research and development in addressing this complex and debilitating condition.
The content above is a summary. For more details, see the source article.